首页> 美国卫生研究院文献>American Journal of Blood Research >Bone marrow angiogenesis and progression in multiple myeloma
【2h】

Bone marrow angiogenesis and progression in multiple myeloma

机译:多发性骨髓瘤的骨髓血管生成和进展

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Multiple myeloma plasma cells home and expand in the bone marrow where cause an unbalanced bone remodelling with increased bone resorption and low bone formation that represent the typical feature in the majority of patients. A clinically relevant aspect of the interactions of multiple myeloma plasma cells in the bone marrow microenvironment is neovascularization, a constant hallmark of disease progression. This process is only partially supported by factors such as vascular endothelial growth factor, fibroblast growth factor-2 and metalloproteinases, which are directly secreted by the tumor cells. In fact, the presence in the bone marrow microenvironment of cytokines, in particular interleukin-6, as a consequence of plasma cell-stromal cell interactions, induces the production and secretion of angiogenic factors by other cells present in the bone microenvironment, thus contributing to the angiogenic switch during the progression of the disease. Near angiogenesis vasculogenesis occur in the bone marrow of myeloma patients and contribute to the vascular three formation. In the bone marrow of myeloma patients haematopoietic stem cells are recruited and induced to differentiate into endothelial cells by the angiogenic cytokines present in the microenvironment. Myeloma plasma cells also induce angiogenesis indirectly via recruitment and activation of stromal inflammatory cells (i.e.: macrophages and mast cells) to secrete their own angiogenic factors. They are recruited and activated by tumor plasma cells through the secretion of fibroblast growth factor-2, interleukin-8, and other chemokines, such as ITAC, Mig, IP-10. When macrophages and mast cells are activated they secrete their angiogenic factors: fibroblast growth factor-2, vascular endothelial growth factor, granulocyte-colony stimulating factor, granulocyte macrophage-colony stimulating factor, which contribute to enhance the tumor neovascularization. Finally, myeloma macrophages when exposed to vascular endothelial growth factor and fibroblast growth factor-2 secreted by plasma cells shows vasculogenic ability and acquire endothelial cell markers and transform into cells functionally and phenotypically similar to paired bone marrow endothelial cells. So they participate to the formation of the bone marrow capillary network (vasculogenic mimicry).
机译:多发性骨髓瘤浆细胞在骨髓中滋生并扩展,在骨髓中引起不平衡的骨骼重塑,骨骼吸收增加,骨骼形成减少,这是大多数患者的典型特征。在骨髓微环境中,多发性骨髓瘤浆细胞相互作用的临床相关方面是新生血管形成,这是疾病进展的一个恒定特征。该过程仅部分由肿瘤细胞直接分泌的因子如血管内皮生长因子,成纤维细胞生长因子-2和金属蛋白酶支持。实际上,由于浆细胞-基质细胞相互作用,在骨髓微环境中存在细胞因子,特别是白细胞介素6,可诱导骨骼微环境中存在的其他细胞产生和分泌血管生成因子,从而有助于在疾病发展过程中的血管生成转换。接近血管生成的血管生成发生在骨髓瘤患者的骨髓中,并有助于血管的三层形成。在骨髓瘤患者的骨髓中,造血干细胞被募集并通过存在于微环境中的血管生成细胞因子被诱导分化为内皮细胞。骨髓瘤浆细胞还通过基质炎症细胞(即巨噬细胞和肥大细胞)的募集和激活间接地诱导血管生成,以分泌其自身的血管生成因子。它们通过分泌成纤维细胞生长因子2,白介素8和其他趋化因子(如ITAC,Mig,IP-10)被肿瘤浆细胞募集并激活。当巨噬细胞和肥大细胞被激活时,它们分泌其血管生成因子:成纤维细胞生长因子-2,血管内皮生长因子,粒细胞集落刺激因子,粒细胞巨噬细胞集落刺激因子,它们有助于增强肿瘤的新血管形成。最后,当暴露于浆细胞分泌的血管内皮生长因子和成纤维细胞生长因子-2时,骨髓瘤巨噬细胞显示出血管生成能力并获得内皮细胞标志物,并在功能和表型上转化为成对的细胞,类似于成对的骨髓内皮细胞。因此,它们参与了骨髓毛细血管网的形成(血管生成模拟)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号